BACKGROUND & AIMS: Although colorectal cancer (CRC) progression has been associated with alterations in KRAS and RAS signaling, not all CRC cells have KRAS gene mutations. RAS activity is modulated by RAS-GTPase-activating proteins (RASGAPs), so we investigated the role of RASGAPs in CRC progression. METHODS: The level of RASGAP expression in CRC cells was analyzed using quantitative real-time polymerase chain reaction. The expression of the RAS protein activator like-1 (RASAL1) was examined in clinical colorectal neoplasms using immunohistochemistry. The clinicopathologic (age, sex, and tumor site and grade) and molecular (KRAS gene mutation, as well as CTNNB1 and TP53 expression patterns) factors that could affect RASAL1 expression were examined. RESULTS: Of 12 RASGAPs examined, expression levels of only RASAL1 decreased in CRC cells; RASAL1 expression decreased in most CRC cells with wild-type KRAS gene but rarely in those with mutant KRAS gene. A transfection assay showed that RASAL1 repressed RAS/mitogen-activated protein kinase signaling in response to growth factor stimulation and reduced proliferation of CRC cells that contained wild-type KRAS gene. RASAL1 expression was detected in 46.9% (30/64) of adenocarcinoma, 17.4% (8/46) of large adenoma, and no (0/42) small adenoma samples. RASAL1 expression levels were correlated with the presence of wild-type KRAS gene in CRC tumor samples (P= .0010), distal location (P= .0066), and abnormal expression of TP53 (P= .0208). CONCLUSIONS: RASAL1 expression is reduced in CRC cells that contain wild-type KRAS gene. Reductions in RASAL1 expression were detected more frequently in advanced lesions than in small adenomas, suggesting that RASAL1 functions in the progression of benign colonic neoplasms.
BACKGROUND & AIMS: Although colorectal cancer (CRC) progression has been associated with alterations in KRAS and RAS signaling, not all CRC cells have KRAS gene mutations. RAS activity is modulated by RAS-GTPase-activating proteins (RASGAPs), so we investigated the role of RASGAPs in CRC progression. METHODS: The level of RASGAP expression in CRC cells was analyzed using quantitative real-time polymerase chain reaction. The expression of the RAS protein activator like-1 (RASAL1) was examined in clinical colorectal neoplasms using immunohistochemistry. The clinicopathologic (age, sex, and tumor site and grade) and molecular (KRAS gene mutation, as well as CTNNB1 and TP53 expression patterns) factors that could affect RASAL1 expression were examined. RESULTS: Of 12 RASGAPs examined, expression levels of only RASAL1 decreased in CRC cells; RASAL1 expression decreased in most CRC cells with wild-type KRAS gene but rarely in those with mutant KRAS gene. A transfection assay showed that RASAL1 repressed RAS/mitogen-activated protein kinase signaling in response to growth factor stimulation and reduced proliferation of CRC cells that contained wild-type KRAS gene. RASAL1 expression was detected in 46.9% (30/64) of adenocarcinoma, 17.4% (8/46) of large adenoma, and no (0/42) small adenoma samples. RASAL1 expression levels were correlated with the presence of wild-type KRAS gene in CRC tumor samples (P= .0010), distal location (P= .0066), and abnormal expression of TP53 (P= .0208). CONCLUSIONS:RASAL1 expression is reduced in CRC cells that contain wild-type KRAS gene. Reductions in RASAL1 expression were detected more frequently in advanced lesions than in small adenomas, suggesting that RASAL1 functions in the progression of benign colonic neoplasms.
Authors: Uta Duppel; Matthias Woenckhaus; Christian Schulz; Johannes Merk; Wolfgang Dietmaier Journal: Oncol Lett Date: 2016-08-01 Impact factor: 2.967
Authors: Jennifer Webster; Tia L Kauffman; Heather Spencer Feigelson; Pamala A Pawloski; Adedayo A Onitilo; Arnold L Potosky; Deanna Cross; Paul R Meier; Anousheh S Mirabedi; Thomas Delate; Yihe Daida; Andrew E Williams; Gwen L Alexander; Catherine A McCarty; Stacey Honda; Lawrence H Kushi; Katrina A B Goddard Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-11-15 Impact factor: 4.254
Authors: Stephen B Keysar; David P Astling; Ryan T Anderson; Brian W Vogler; Daniel W Bowles; J Jason Morton; Jeramiah J Paylor; Magdalena J Glogowska; Phuong N Le; Justin R Eagles-Soukup; Severine L Kako; Sarah M Takimoto; Daniel B Sehrt; Adrian Umpierrez; Morgan A Pittman; Sarah M Macfadden; Ryan M Helber; Scott Peterson; Diana F Hausman; Sherif Said; Ted H Leem; Julie A Goddard; John J Arcaroli; Wells A Messersmith; William A Robinson; Fred R Hirsch; Marileila Varella-Garcia; David Raben; Xiao-Jing Wang; John I Song; Aik-Choon Tan; Antonio Jimeno Journal: Mol Oncol Date: 2013-04-04 Impact factor: 6.603